Lyell Immunopharma’s (LYEL) Buy Rating Reaffirmed at HC Wainwright

Posted by Brenda Bartman on Jun 9th, 2026

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $45.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 265.56% from the company’s current price.

Several other equities analysts have also recently weighed in on LYEL. Robert W. Baird set a $49.00 price target on Lyell Immunopharma and gave the company an “outperform” rating in a report on Thursday, April 30th. Zacks Research raised Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Citizens Jmp started coverage on Lyell Immunopharma in a report on Monday, March 9th. They set a “market outperform” rating and a $34.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a report on Monday. Finally, Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Lyell Immunopharma currently has an average rating of “Moderate Buy” and a consensus price target of $43.00.

View Our Latest Stock Report on Lyell Immunopharma

Lyell Immunopharma Trading Up 2.8%

LYEL stock opened at $12.31 on Tuesday. The stock has a market capitalization of $287.24 million, a PE ratio of -0.89 and a beta of -0.09. Lyell Immunopharma has a 12-month low of $8.46 and a 12-month high of $45.00. The stock’s 50 day simple moving average is $19.71 and its 200 day simple moving average is $23.43.

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.10). The business had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%. On average, research analysts predict that Lyell Immunopharma will post -7.87 earnings per share for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently bought and sold shares of LYEL. AQR Capital Management LLC increased its stake in Lyell Immunopharma by 773.5% in the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares in the last quarter. Marshall Wace LLP purchased a new stake in Lyell Immunopharma in the 2nd quarter worth $94,000. Bridgeway Capital Management LLC purchased a new position in shares of Lyell Immunopharma during the second quarter valued at about $159,000. BBR Partners LLC purchased a new position in shares of Lyell Immunopharma during the fourth quarter valued at about $210,000. Finally, Walleye Capital LLC purchased a new position in shares of Lyell Immunopharma during the second quarter valued at about $258,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

(Get Free Report)

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.